Genovis AB
GENO
Company Profile
Business description
Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.
Contact
Scheelevagen 2
Box 790
LundSE-220 07
SWET: +46 46101230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
32
Stocks News & Analysis
stocks
Should you invest in small caps?
With small capitalisation stocks gaining momentum, there are important considerations to determine whether they are right for your portfolio.
stocks
3 no moat companies that might surprise you
Moats are rare but worth looking for. These three ASX listed companies own iconic brands but don't make the cut according to our analysts.
stocks
Are investors too optimistic about ASX listed data centre provider?
Move to cloud and AI driving strong data centre industry demand.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,612.60 | 48.60 | -0.56% |
| CAC 40 | 7,194.51 | 62.96 | -0.87% |
| DAX 40 | 19,295.98 | 109.22 | -0.56% |
| Dow JONES (US) | 44,860.31 | 123.74 | 0.28% |
| FTSE 100 | 8,258.61 | 33.07 | -0.40% |
| HKSE | 19,159.20 | 8.21 | 0.04% |
| NASDAQ | 19,174.30 | 119.46 | 0.63% |
| Nikkei 225 | 38,442.00 | 338.14 | -0.87% |
| NZX 50 Index | 13,064.16 | 49.60 | -0.38% |
| S&P 500 | 6,021.63 | 34.26 | 0.57% |
| S&P/ASX 200 | 8,359.40 | 58.20 | -0.69% |
| SSE Composite Index | 3,259.76 | 4.00 | -0.12% |